Detailed timing of reocclusion and restenosis in endovascular therapy of the femoropopliteal lesions

Background: Drug-eluting device and covered stent have become the mainstream of endovascular therapy for femoropopliteal lesions. Though there have been many reports on the primary patency of each device, there are few detailed data on restenosis and reocclusion. This was a physician-initiated, multicenter, retrospective study. From 7 institutes, 3635 femoropopliteal cases were enrolled in this study. Among them, we studied 2786 cases treated with drug-eluting stent (DES), drug-coated balloon (DCB), covered stent (CS), and bare nitinol stent (BNS). Results : The lesion background for each device was different, with mean lesion lengths of 140 (80-220) mm for BNS, 250 (180-300) mm for CS, 200 (100-260) mm for DES, and 123 (60-216) mm for DCB (P<0.001). Primary patency at 2 years was 62% for BNS, 75% for CS, 74% for DES, and 65% for DCB. Timing of restenosis and reocclusion were also different for each device. Peak restenosis timing was 6-9 months for BNS and DCB, 12-15 months for CS and DES. The timing of reocclusion was 6-9 months for BNS and DES, 3-6 months for CS, and 0-3 months for DCB. Conclusions : Not only were the primary patency for each device different, but the timing of restenosis and reocclusion for each device was also different.